Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma: Anticipated Q1 Outperformance and Sustained Buy Rating Despite Rising R&D Expenses
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $53
BridgeBio Pharma Is Maintained at Buy by HC Wainwright & Co.
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Raymond James Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $57
BridgeBio Pharma Analyst Ratings
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
BridgeBio Pharma Analyst Ratings
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $50
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)
BridgeBio Pharma: Strong Buy Rating Backed by Competitive Positioning and Growth Potential
UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $65